ArticleBMC pediatrics2026
Neurological adverse events of blinatumomab in children with B-cell acute lymphoblastic leukemia: a retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to conduct a real-world analysis of blinatumomab-associated neurological adverse events (NAEs) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) to comprehensively elucidate its safety profile.
methodsA retrospective analysis was conducted in children with B-ALL who were treated at hematology medical ward of our institution from January 2024 to December 2025. Document the occurrence of all NAEs during the dosing cycle of blinatumomab, including the time of occurrence, cycle of appearance, severity, management, and outcome.
resultsThere were 13 individuals with an average age of 10.08 ± 4.23 years experienced a total of 18 NAEs among all the 60 B-ALL patients. These NAEs primarily manifest as headache, dizziness, tremor, delirium, status epilepticus, and cerebral herniation. Most NAEs occur during the first cycle of medication (77.78%). The median onset time of the NAEs was approximately 9.5 days, with a duration of approximately 2.78 ± 2.21 days. The majority of NAEs associated with blinatumomab are mild to moderate in severity (grade 1 or 2) (88.89%). Two patients experienced severe adverse events (AEs) (grade 4), manifesting as status epilepticus and cerebral herniation. There were statistically significant differences in age (10.08 ± 4.23 vs. 5.40 ± 3.57; P < 0.01), and the proportion of males (84.62% vs. 55.32%; P = 0.03) between the group with NAEs and without. Additionally, we found age was identified as an independent predictor of blinatumomab-associated NAEs.
conclusionThis study reveals real-world data on the neurological safety profile of blinatumomab, characterizes the features of it, and identifies age as an independent predictor of blinatumomab-associated NAEs in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.